Clinical Scorecard: Treatment of Locally Advanced Rectal Cancer Associated with Lynch Syndrome During Pregnancy Using Neoadjuvant Immunochemotherapy: A Case Study

At a Glance

Key Highlights

• Lynch syndrome increases colorectal cancer risk by 40-80%.
• Neoadjuvant immunochemotherapy achieved significant tumor regression.
• Medical termination of pregnancy was performed due to fetal viability concerns.
• Patient remained disease-free at 24 months follow-up.
• Multidisciplinary management is crucial for optimizing outcomes.

Guideline-Based Recommendations

Diagnosis

• Use imaging (ultrasonography, MRI) and colonoscopy for diagnosis.
• Histopathological confirmation of adenocarcinoma with immunohistochemistry for Lynch syndrome.

Management

• Consider medical termination of pregnancy in cases of poor fetal viability.
• Administer neoadjuvant chemoradiotherapy followed by surgical resection.

Monitoring & Follow-up

• Regular follow-up with imaging and serum tumor markers post-treatment.

Risks

• Potential teratogenic effects of systemic therapy during pregnancy.
• Genetic implications for offspring due to Lynch syndrome.

Patient & Prescribing Data

Pregnant women diagnosed with locally advanced rectal cancer and Lynch syndrome.

Combination of capecitabine, oxaliplatin, and tislelizumab was effective with manageable side effects.

Clinical Best Practices

• Engage in shared decision-making with patients regarding treatment options.
• Incorporate genetic counseling into the management plan.
• Utilize a multidisciplinary approach for complex cases.

Related Resources & Content

• Lynch Syndrome Overview
• Colorectal Cancer Risk in Lynch Syndrome
• Management of Colorectal Cancer During Pregnancy